Details for: SEPTIN9
Gene ID: 10801
Gene Type: Protein-coding - A gene that serves as a template for producing a messenger RNA (mRNA) molecule, which is then translated into a functional protein.
Symbol: SEPTIN9
Ensembl ID: ENSG00000184640
Description: septin 9
Selected Context(s): Overall
Cell Significance Landscape
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 84.94rCSI 65.44%PRS 16.3
-
CSI 53.47rCSI 61.21%PRS 35.84
-
CSI 48.87rCSI 32.92%PRS 21.51
-
CSI 47rCSI 47.9%PRS 25.4
-
CSI 32.48rCSI 22.68%PRS 18.79
-
CSI 25.17rCSI 63.06%PRS 48.28
-
CSI 22.87rCSI 17.11%PRS 28.27
-
CSI 22.22rCSI 27.49%PRS 15.49
-
CSI 21.96rCSI 19.09%PRS 22.09
-
CSI 19.74rCSI 26.38%PRS 33.58
-
CSI 19.3rCSI 55.1%PRS 30.37
-
CSI 18.88rCSI 49.05%PRS 22.83
-
CSI 18.16rCSI 27.74%PRS 17.78
-
CSI 16.31rCSI 11.45%PRS 42.21
-
CSI 14.06rCSI 37.9%PRS 22.85
-
CSI 10.96rCSI 19.62%PRS 16.32
-
CSI 10.75rCSI 20.91%PRS 18.07
-
CSI 10.56rCSI 28.22%PRS 14.65
-
CSI 10.44rCSI 7.89%PRS 24.33
-
CSI 9.84rCSI 7.63%PRS 16.91
-
CSI 8.28rCSI 10.3%PRS 18.73
-
CSI 8.13rCSI 6.73%PRS 17.9
-
CSI 8.04rCSI 28.59%PRS 52.59
-
CSI 7.72rCSI 9.7%PRS 64.17
-
CSI 7.7rCSI 11.82%PRS 21.06
-
CSI 7.48rCSI 22.19%PRS 24.9
-
CSI 6.94rCSI 20.7%PRS 41.43
-
CSI 6.77rCSI 8.5%PRS 22.87
-
CSI 6.73rCSI 6.21%PRS 18.25
-
CSI 6.53rCSI 8.42%PRS 10.92
-
CSI 6.28rCSI 8.88%PRS 24.44
-
CSI 6.05rCSI 15.36%PRS 13.37
-
CSI 5.72rCSI 5.5%PRS 35.96
-
CSI 5.55rCSI 4.86%PRS 23.54
-
CSI 5.34rCSI 28.05%PRS 30.56
-
CSI 5.07rCSI 3.38%PRS 43.49
-
CSI 4.89rCSI 11.65%PRS 20.51
-
CSI 4.65rCSI 10.19%PRS 23.68
-
CSI 4.61rCSI 8.08%PRS 13.22
-
CSI 4.45rCSI 20.57%PRS 36.54
-
CSI 4.04rCSI 12.95%PRS 25.46
-
CSI 4.02rCSI 3.33%PRS 16.73
-
CSI 3.97rCSI 6.27%PRS 17.76
-
CSI 3.94rCSI 6.36%PRS 27.51
-
CSI 3.9rCSI 2.3%PRS 24.59
-
CSI 3.79rCSI 3.83%PRS 70.33
-
CSI 3.67rCSI 5.09%PRS 25.15
-
CSI 3.6rCSI 14.02%PRS 24.04
-
CSI 3.55rCSI 9.17%PRS 16.46
-
CSI 3.45rCSI 3.6%PRS 18.1
-
CSI 3.43rCSI 5.03%PRS 18.69
-
CSI 3.41rCSI 3%PRS 20.27
-
CSI 3.3rCSI 5.82%PRS 10.38
-
CSI 3.27rCSI 5.1%PRS 40.99
-
CSI 3.26rCSI 9.63%PRS 21.32
-
CSI 3.24rCSI 2.78%PRS 29.26
-
CSI 3.24rCSI 4.45%PRS 35.59
-
CSI 3.23rCSI 3.97%PRS 51.27
-
CSI 3.1rCSI 7.43%PRS 31.51
-
CSI 3.05rCSI 4.88%PRS 19.35
-
CSI 3.03rCSI 2.11%PRS 25.16
-
CSI 3.01rCSI 7.93%PRS 34.2
-
CSI 3rCSI 2.16%PRS 24.26
-
CSI 2.99rCSI 34.66%PRS 60.47
-
CSI 2.95rCSI 3.17%PRS 16.28
-
CSI 2.92rCSI 3.99%PRS 20.01
-
CSI 2.89rCSI 15.65%PRS 55.69
-
CSI 2.76rCSI 3.36%PRS 22.22
-
CSI 2.75rCSI 64.03%PRS 82.48
-
CSI 2.63rCSI 5.01%PRS 28.03
-
CSI 2.58rCSI 4.14%PRS 49.7
-
CSI 2.56rCSI 27.81%PRS 33.59
-
CSI 2.53rCSI 2.19%PRS 19.89
-
CSI 2.52rCSI 7.17%PRS 20.4
-
CSI 2.49rCSI 5.68%PRS 15.19
-
CSI 2.49rCSI 3.33%PRS 59.94
-
CSI 2.48rCSI 2.45%PRS 59.63
-
CSI 2.46rCSI 5.08%PRS 26.51
-
CSI 2.44rCSI 1.96%PRS 31.66
-
CSI 2.37rCSI 3.24%PRS 19.57
-
CSI 2.34rCSI 2.45%PRS 18.49
-
CSI 2.31rCSI 2.8%PRS 22.33
-
CSI 2.28rCSI 3.51%PRS 24.39
-
CSI 2.28rCSI 1.77%PRS 25.79
-
CSI 2.28rCSI 2.1%PRS 31.95
-
CSI 2.27rCSI 2.38%PRS 18.88
-
CSI 2.27rCSI 5.92%PRS 27.23
-
CSI 2.23rCSI 34.46%PRS 42.82
-
CSI 2.21rCSI 1.65%PRS 48.35
-
CSI 2.2rCSI 3.61%PRS 13.58
-
CSI 2.19rCSI 2.98%PRS 41.47
-
CSI 2.16rCSI 3.44%PRS 15.16
-
CSI 2.1rCSI 2.44%PRS 48.77
-
CSI 2.1rCSI 1.67%PRS 31.36
-
CSI 2.05rCSI 2.55%PRS 25.02
-
CSI 2.04rCSI 1.53%PRS 18.68
-
CSI 2.03rCSI 3.85%PRS 46.76
-
CSI 2.03rCSI 10.89%PRS 31.4
-
CSI 2rCSI 6.5%PRS 21.4
-
CSI 1.96rCSI 4.56%PRS 40.89
-
CSI -1.9rCSI -9.0%PRS 13.1%
-
CSI -1.4rCSI -4.0%PRS 13.5%
-
CSI 0.1rCSI 0.2%PRS 28.7%
-
CSI 0.1rCSI 3.2%PRS 83.9%
-
CSI 0.1rCSI 0.7%PRS 25.9%
-
CSI 0.1rCSI 0.1%PRS 15.9%
-
CSI 0.1rCSI 0.2%PRS 28.6%
-
CSI 0.2rCSI 3.4%PRS 71.7%
-
CSI 0.2rCSI 4.5%PRS 68.2%
-
CSI 0.2rCSI 0.5%PRS 12.7%
-
CSI 0.3rCSI 2.2%PRS 28.4%
-
CSI 0.3rCSI 1.5%PRS 52.8%
-
CSI 0.3rCSI 1.8%PRS 44.3%
-
CSI 0.3rCSI 3.1%PRS 53.6%
-
CSI 0.3rCSI 0.8%PRS 29.0%
-
CSI 0.3rCSI 0.4%PRS 28.0%
-
CSI 0.3rCSI 2.0%PRS 34.1%
-
CSI 0.3rCSI 2.9%PRS 46.4%
-
CSI 0.3rCSI 0.5%PRS 22.8%
-
CSI 0.3rCSI 3.1%PRS 47.0%
-
CSI 0.3rCSI 4.6%PRS 89.9%
-
CSI 0.3rCSI 0.4%PRS 30.6%
-
CSI 0.3rCSI 1.3%PRS 29.1%
-
CSI 0.3rCSI 1.5%PRS 9.9%
-
CSI 0.3rCSI 2.2%PRS 52.4%
-
CSI 0.4rCSI 8.2%PRS 32.8%
-
CSI 0.4rCSI 1.3%PRS 30.3%
-
CSI 0.4rCSI 2.1%PRS 9.1%
-
CSI 0.4rCSI 0.8%PRS 35.3%
-
CSI 0.4rCSI 0.8%PRS 39.4%
-
CSI 0.4rCSI 0.7%PRS 24.0%
-
CSI 0.4rCSI 1.8%PRS 32.7%
-
CSI 0.4rCSI 1.2%PRS 24.0%
-
CSI 0.4rCSI 0.5%PRS 10.2%
-
CSI 0.4rCSI 0.3%PRS 17.7%
-
CSI 0.4rCSI 4.3%PRS 74.5%
-
CSI 0.4rCSI 0.8%PRS 26.9%
-
CSI 0.4rCSI 1.9%PRS 31.0%
-
CSI 0.5rCSI 1.5%PRS 28.6%
-
CSI 0.5rCSI 2.6%PRS 22.8%
-
CSI 0.5rCSI 1.4%PRS 20.0%
-
CSI 0.5rCSI 2.3%PRS 56.5%
-
CSI 0.5rCSI 0.8%PRS 20.2%
-
CSI 0.5rCSI 1.2%PRS 18.3%
-
CSI 0.5rCSI 0.6%PRS 27.2%
-
CSI 0.5rCSI 1.9%PRS 9.8%
-
CSI 0.5rCSI 5.5%PRS 23.4%
-
CSI 0.5rCSI 1.3%PRS 16.3%
-
CSI 0.6rCSI 2.3%PRS 43.2%
-
CSI 0.6rCSI 0.8%PRS 24.8%
-
CSI 0.6rCSI 0.7%PRS 17.3%
-
CSI 0.6rCSI 5.4%PRS 63.5%
-
CSI 0.6rCSI 2.3%PRS 30.5%
-
CSI 0.6rCSI 8.0%PRS 69.6%
-
CSI 0.6rCSI 1.2%PRS 43.4%
-
CSI 0.6rCSI 0.9%PRS 20.2%
-
CSI 0.6rCSI 0.9%PRS 31.1%
-
CSI 0.6rCSI 4.6%PRS 46.2%
-
CSI 0.6rCSI 2.3%PRS 57.0%
-
CSI 0.6rCSI 4.6%PRS 34.0%
-
CSI 0.7rCSI 0.9%PRS 26.7%
-
CSI 0.7rCSI 1.3%PRS 22.2%
-
CSI 0.7rCSI 2.2%PRS 21.4%
-
CSI 0.7rCSI 0.6%PRS 18.5%
-
CSI 0.7rCSI 1.5%PRS 28.1%
-
CSI 0.7rCSI 1.6%PRS 10.9%
-
CSI 0.7rCSI 1.2%PRS 20.9%
-
CSI 0.7rCSI 1.0%PRS 26.5%
-
CSI 0.7rCSI 0.8%PRS 20.8%
-
CSI 0.7rCSI 4.6%PRS 53.3%
-
CSI 0.8rCSI 5.3%PRS 49.6%
-
CSI 0.8rCSI 1.0%PRS 17.2%
-
CSI 0.8rCSI 0.8%PRS 30.6%
-
CSI 0.8rCSI 0.7%PRS 20.6%
-
CSI 0.8rCSI 1.8%PRS 26.2%
-
CSI 0.8rCSI 1.7%PRS 34.6%
-
CSI 0.8rCSI 3.5%PRS 17.3%
-
CSI 0.8rCSI 1.8%PRS 17.2%
-
CSI 0.8rCSI 1.4%PRS 23.2%
-
CSI 0.8rCSI 1.9%PRS 21.9%
-
CSI 0.8rCSI 1.8%PRS 11.5%
-
CSI 0.8rCSI 3.7%PRS 46.2%
-
CSI 0.8rCSI 2.7%PRS 18.5%
-
CSI 0.8rCSI 1.1%PRS 19.4%
-
CSI 0.9rCSI 0.8%PRS 26.9%
-
CSI 0.9rCSI 2.0%PRS 35.6%
-
CSI 0.9rCSI 3.5%PRS 37.4%
-
CSI 0.9rCSI 2.6%PRS 37.9%
-
CSI 0.9rCSI 3.0%PRS 10.4%
-
CSI 0.9rCSI 1.2%PRS 20.5%
-
CSI 0.9rCSI 4.0%PRS 32.8%
-
CSI 0.9rCSI 1.6%PRS 13.5%
-
CSI 0.9rCSI 2.0%PRS 20.4%
-
CSI 0.9rCSI 1.6%PRS 29.5%
-
CSI 0.9rCSI 3.3%PRS 31.1%
-
CSI 0.9rCSI 3.5%PRS 10.7%
-
CSI 0.9rCSI 1.2%PRS 19.4%
-
CSI 0.9rCSI 1.8%PRS 34.6%
-
CSI 1.0rCSI 10.4%PRS 31.5%
-
CSI 1.0rCSI 2.9%PRS 16.0%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 1819031547
Symbol: SEPT9_HUMAN
Name: Septin-9
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 10339604
Title: MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).
PubMed ID: 10339604
PubMed ID: 10987277
Title: Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors.
PubMed ID: 10987277
PubMed ID: 10673329
Title: Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors.
PubMed ID: 10673329
PubMed ID: 14702039
Title: Complete sequencing and characterization of 21,243 full-length human cDNAs.
PubMed ID: 14702039
DOI: 10.1038/ng1285
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 10231032
Title: Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.
PubMed ID: 10231032
PubMed ID: 17974005
Title: The full-ORF clone resource of the German cDNA consortium.
PubMed ID: 17974005
PubMed ID: 11593400
Title: Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3.
PubMed ID: 11593400
PubMed ID: 15485874
Title: Biochemical and cell biological analyses of a mammalian septin complex, Sept7/9b/11.
PubMed ID: 15485874
PubMed ID: 15915442
Title: Expression profiling the human septin gene family.
PubMed ID: 15915442
DOI: 10.1002/path.1789
PubMed ID: 15558029
Title: Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin.
PubMed ID: 15558029
PubMed ID: 16007136
Title: Possible role of Rho/Rhotekin signaling in mammalian septin organization.
PubMed ID: 16007136
PubMed ID: 17081983
Title: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.
PubMed ID: 17081983
PubMed ID: 16964243
Title: A probability-based approach for high-throughput protein phosphorylation analysis and site localization.
PubMed ID: 16964243
DOI: 10.1038/nbt1240
PubMed ID: 17546647
Title: SEPT9 sequence alternations causing hereditary neuralgic amyotrophy are associated with altered interactions with SEPT4/SEPT11 and resistance to Rho/Rhotekin-signaling.
PubMed ID: 17546647
DOI: 10.1002/humu.20554
PubMed ID: 17922164
Title: Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-specific septin.
PubMed ID: 17922164
PubMed ID: 18220336
Title: Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.
PubMed ID: 18220336
DOI: 10.1021/pr0705441
PubMed ID: 18669648
Title: A quantitative atlas of mitotic phosphorylation.
PubMed ID: 18669648
PubMed ID: 19413330
Title: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach.
PubMed ID: 19413330
DOI: 10.1021/ac9004309
PubMed ID: 19145258
Title: Septins regulate bacterial entry into host cells.
PubMed ID: 19145258
PubMed ID: 19690332
Title: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
PubMed ID: 19690332
PubMed ID: 20068231
Title: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
PubMed ID: 20068231
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 21406692
Title: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
PubMed ID: 21406692
PubMed ID: 22814378
Title: N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB.
PubMed ID: 22814378
PubMed ID: 23186163
Title: Toward a comprehensive characterization of a human cancer cell phosphoproteome.
PubMed ID: 23186163
DOI: 10.1021/pr300630k
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 25944712
Title: N-terminome analysis of the human mitochondrial proteome.
PubMed ID: 25944712
PubMed ID: 16186812
Title: Mutations in SEPT9 cause hereditary neuralgic amyotrophy.
PubMed ID: 16186812
DOI: 10.1038/ng1649
PubMed ID: 18492087
Title: Dysmorphic syndrome of hereditary neuralgic amyotrophy associated with a SEPT9 gene mutation -- a family study.
PubMed ID: 18492087
PubMed ID: 19451530
Title: SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy.
PubMed ID: 19451530
Sequence Information:
- Length: 586
- Mass: 65401
- Checksum: D4404578328CFCFE
- Sequence:
MKKSYSGGTR TSSGRLRRLG DSSGPALKRS FEVEEVETPN STPPRRVQTP LLRATVASST QKFQDLGVKN SEPSARHVDS LSQRSPKASL RRVELSGPKA AEPVSRRTEL SIDISSKQVE NAGAIGPSRF GLKRAEVLGH KTPEPAPRRT EITIVKPQES AHRRMEPPAS KVPEVPTAPA TDAAPKRVEI QMPKPAEAPT APSPAQTLEN SEPAPVSQLQ SRLEPKPQPP VAEATPRSQE ATEAAPSCVG DMADTPRDAG LKQAPASRNE KAPVDFGYVG IDSILEQMRR KAMKQGFEFN IMVVGQSGLG KSTLINTLFK SKISRKSVQP TSEERIPKTI EIKSITHDIE EKGVRMKLTV IDTPGFGDHI NNENCWQPIM KFINDQYEKY LQEEVNINRK KRIPDTRVHC CLYFIPATGH SLRPLDIEFM KRLSKVVNIV PVIAKADTLT LEERVHFKQR ITADLLSNGI DVYPQKEFDE DSEDRLVNEK FREMIPFAVV GSDHEYQVNG KRILGRKTKW GTIEVENTTH CEFAYLRDLL IRTHMQNIKD ITSSIHFEAY RVKRLNEGSS AMANGMEEKE PEAPEM
Genular Protein ID: 488744189
Symbol: A0A0S2Z5A5_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 26871637
Title: Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.
PubMed ID: 26871637
Sequence Information:
- Length: 568
- Mass: 63666
- Checksum: 47A03DD79B5D6147
- Sequence:
MERDRISALK RSFEVEEVET PNSTPPRRVQ TPLLRATVAS STQKFQDLGV KNSEPSARHV DSLSQRSPKA SLRRVELSGP KAAEPVSRRT ELSIDISSKQ VENAGAIGPS RFGLKRAEVL GHKTPEPAPR RTEITIVKPQ ESAHRRMEPP ASKVPEVPTA PATDAAPKRV EIQMPKPAEA PTAPSPAQTL ENSEPAPVSQ LQSRLEPKPQ PPVAEATPRS QEATEAAPSC VGDMADTPRD AGLKQAPASR NEKAPVDFGY VGIDSILEQM RRKAMKQGFE FNIMVVGQSG LGKSTLINTL FKSKISRKSV QPTSEERIPK TIEIKSITHD IEEKGVRMKL TVIDTPGFGD HINNENCWQP IMKFINDQYE KYLQEEVNIN RKKRIPDTRV HCCLYFIPAT GHSLRPLDIE FMKRLSKVVN IVPVIAKADT LTLEERVHFK QRITADLLSN GIDVYPQKEF DEDSEDRLVN EKFREMIPFA VVGSDHEYQV NGKRILGRKT KWGTIEVENT THCEFAYLRD LLIRTHMQNI KDITSSIHFE AYRVKRLNEG SSAMANGMEE KEPEAPEM